Stage I Intraocular Melanoma Recruiting Phase 2 Trials for Sunitinib (DB01268)

IndicationStatusPhase
DBCOND0069188 (Stage I Intraocular Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02068586Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal MelanomaTreatment